ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medi...(This study funded by the U.S.National In...),Health

Date:10/3/2007

This study, funded by the U.S. National Institutes of Health, was initiated in 2005 and has involved more than 2,500 asymptomatic patients aged 50 or over at 15 centres across the U.S. Patients were investigated using both procedures and the resulting CT images were read by a panel of radiologists. The headline results of the study, released at the ACRIN 2007 Fall Meeting in Arlington, Virginia, on September 28, demonstrate convincingly that CT colonography is at least as sensitive and specific as conventional colonoscopy in detecting adenomas of 1 cm diameter or larger.

Colorectal cancer is the second leading cause of cancer death in the U.S. When colorectal cancer is detected early the survival rate is high. Those most at risk, aged 50 or older, are recommended to be screened regularly. However less than half actually undergo colonoscopy. Conventional optical colonoscopy, involving the insertion of a flexible metal tube into the colon, remains the "gold standard" for detection of early-stage tumours, not least because tissue samples can be taken at the same time as they are visualised. However CT colonography is non-invasive, less uncomfortable for the patient and offers the potential of routine screening. The results of the ACRIN 6664 study are expected to lead to reimbursement for CT colonography by Medicare and health insurance companies and thereby drive wider adoption of this technique and increased levels of screening in the at-risk population.

Dr Stuart Taylor of University College Hospital, a principal investigator for Medicsight, commented: "This very well designed study is the largest to date which has specifically investigated the use of CT colonography to screen for colorectal neoplasia in asymptomatic individuals, and has produced very positive results. The 90% sensitivity for identifying patients harbouring a 1 cm adenoma essentially validates the previously reported excellent performance of screening CT colonography by Dr Perry Pickhardt
'/>"/>

SOURCE MGT Capital Investments, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea